You may be eligible to participate in a study evaluating a new drug for individuals with higher-risk MDS, which aims to enhance the effectiveness of standard chemotherapy treatment.
You may be able to participate in this MDS clinical study if you:
Are 18 years of age or older
Have been diagnosed with higher-risk MDS
Higher-risk includes:
Have been diagnosed with MDS and previously treated with a hypomethylating agent such as Azacitidine (Vidaza) or Decitabine (Dacogen or Inqovi)
You do not qualify if you have:
By enrolling in this Phase I/II study, you may receive:
Access to physicians with extensive experience in managing MDS
Study drug at no cost to you
Travel, lodging, and meal reimbursements for study visits
The purpose of this MDS study is to evaluate a study drug that may help improve the immune response and overall treatment outcomes for patients with MDS when combined with standard chemotherapy (azacitidine).
By enrolling in this Phase I/II study, you may participate in clinical research looking to determine if the study drug can enhance your immune system’s response to standard chemotherapy (azacitidine) and reduce your cancer.
You will be seen by MDS experts and help advance research about treatment for MDS.
Click here to see if you may qualify for the study. Then, select a date and time for a short phone call with a PatientWing representative. Applying is voluntary and doesn’t require commitment to study participation.
If initially eligible, a PatientWing representative will call you to discuss the study, additional eligibility criteria, and answer your questions. If you are still eligible at the end of this screening call, you’ll be connected to a member of the team at a study site location.
The team at a participating study site will determine if you are eligible to participate in the study by reviewing your medical records. You will have the opportunity to ask questions and make an informed decision about your participation.
This study will consist of weekly or biweekly study visits. On average, patients participate in the study for 6-10 months, but you may continue treatment longer based on the opinion of the study doctor.
The family, friends, and healthcare teams of those with MDS play an important role in supporting their loved one's health and wellbeing. If you are a caregiver of someone with MDS, you can apply for the study on their behalf by clicking the button below.
You have the option to either enter the patient's information or your own contact information. Please speak with the patient prior to entering their information.
Faron Pharmaceuticals is a European clinical-stage biopharmaceutical company based in Finland that is developing novel treatments for cancer. The company is dedicated to developing therapies that make a real difference in patients’ lives, while striving to understand and enhance the entire patient experience.
Our mission to bring better treatments to more people faster starts with you. We help sponsors find patients to participate in their clinical studies. With our focus on rare diseases and expertise in navigating the enrollment process, we're here for you every step of the way.
Call, email us, or fill out the form. We’re here to help.
Receive marketing communications from PatientWing such as patient stories and relevant clinical trial opportunities.
